Helicobacter Pylori Infections Treatment Market to expand at a 7.04% value CAGR by 2033

The global helicobacter pylori infections treatment market is predicted to reach US$ 638.3 Million in 2023, with a compound annual growth rate (CAGR) of 7.04% anticipated from 2023 to 2033, reaching US$ 1,260 Million. The spread of such infections can be attributed to a number of factors, including a lack of adequate water supply, poor sanitation, a large population, and poor personal hygiene. One of the factors influencing the Helicobacter pylori diagnostics market’s growth is increased awareness of H. pylori infections in the cohort.

Antibiotic availability and affordability, as well as quicker processing times, will boost antibiotic use and the need for pre and post-surveillance tests. Furthermore, rising H. pylori infection rates, the need for early symptom diagnosis, and technological advances in diagnostic methods are expected to fuel overall growth over the forecast period.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16291

The key drivers of the industry are the increasing prevalence of communicable diseases and rising public awareness about infections. Tuberculosis, Chlamydia, gonorrhea, other sexually transmitted diseases (STDs), stomach flu (gastroenteritis), and bladder infections are the most common viral infections (UTIs). North America is expected to dominate the global helicobacter pylori diagnostics industry over the forecasted timespan. The rise can be linked to factors such as an increase in disease transmission, increased awareness of communicable diseases, and the launch of new products.

Key Takeaways from Market Study

  • Global helicobacter pylori treatment market to expand nearly 2x from 2023 to 2033
  • By 2023, Europe is expected to have the second-highest H. pylori sales volume, with 30% revenue.
  • In terms of total revenue, hospitals and diagnostics laboratories accounted for more than 82% of the industry share in 2021.
  • The global helicobacter pylori infections market is expected to be worth US$ 1,260 Million
  • The global market for helicobacter pylori infections is estimated to be worth US$ 638.3 Million

“With a rise in the prevalence of chronic diseases, demand for helicobacter pylori treatment is rising, paving way for new approaches to treatment and therapeutics,” remarks an analyst at FMI.

Ask Our Analyst More about Report@ https://www.futuremarketinsights.com/ask-question/rep-gb-16291

Market Competition

Key players in the Helicobacter Pylori Infections Market are:

  • Phathom Pharmaceuticals
  • Redhill Biopharma
  • Takeda Pharmaceuticals
  • AbbVie
  • Cumberland Pharmaceuticals
  • Eisai Co.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche
  • Alpha Laboratories
  • Biohit
  • In May 2022, Biomerica, Inc. received CE Mark for its hp+detect diagnostic test for Helicobacter pylori bacteria. Following product registration in each nation where it is sold, the company plans to market and sell its hp+detect diagnostic test in the European Union (EU) and other international markets.
  • Otsuka launched QuickNaviTM-H. Pylori, a Helicobacter pylori Quick Detection Kit, in April 2021. The diagnostic kit employs the immunochromatography technique to determine the presence or absence of Helicobacter pylori antigens in a stool sample.
  • In July 2022, Bio Rad introduced Platelia H. pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies. Serology is a non-invasive, delicate, and simple method for determining H. pylori infection. To evaluate the quality of IgG antibodies, the Platelia H. pylori IgG immunoenzymatic assay is used.

Want More Insights:

North America is the largest helicobacter pylori infections market due to the high prevalence of the infection in the region. The United States dominates the market in North America, with a large patient population and well-established healthcare infrastructure. The country has also approved several drugs for the treatment of H. pylori infections, such as clarithromycin, amoxicillin, and metronidazole.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16291

Key Segments Profiled in the Helicobacter Pylori Infections Treatment Market Industry Survey 

By Treatment:

  • Bismuth-quadruple Therapy
  • Concomitant Therapy
  • Levofloxacin Triple Therapy
  • Bismuth Therapy
  • High-dose Dual Therapy

By Application:

  • Hospitals
  • Diagnostics Laboratories
  • Clinics

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

About the Author

Ronak Shah

Associate Vice President at Future Market Insights is deeply committed to uncovering actionable insights for consumer and food and beverage players. She brings a unique blend of analysis, industry trends, and consumer behavior to put data into perspective.

What she makes out of data becomes a delight to read. She has authored many opinions, including for publications like Process Industry Informer and Spinal Surgery News, as she understands the market pulse and consumers' shifting preferences.

She likes to bring experts to a roundtable to weigh the impact of a trend on an industry. Catch up with her discussion on the impact of AI in packaging.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these